Article in Trends in molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
Abhay P SagareDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; These authors contributed equally to this work.
Melanie D SweeneyDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; These authors contributed equally to this work.
Amy R NelsonDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; These authors contributed equally to this work.
Zhen ZhaoDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Berislav V ZlokovicDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: zlokovic@usc.edu.
University of Southern California · US
Funding
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRASKIE, MEREDITH NICOLE · 1985 to 2019
$41.0M
Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARTHUR W TOGA · 2016 to 2026
$28.4M
Alzheimer's Abeta, Tau, Apolipoproteins and Blood-brain barrierR01NS034467 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 1995 to 2024
$9.1M
The role of pericytes in the aging brain and pathogenesis and treatment of neurodegeneration, and Alzheimer's A-beta and tau pathologyRF1AG039452 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ICHIDA, JUSTIN KAWIKA · 2019 to 2019
$4.0M
The role of pericytes in white matter diseaseR01NS100459 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 2016 to 2020
$3.6M
Alzheimer's Abeta, apolipoproteins and blood-brain barrierR37NS034467 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 2007 to 2013
$3.4M
Activated protein C system in stroke modelsR01NS090904 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 2014 to 2018
$3.2M
Cerebrovascular beta-Amyloidosis: A-beta CNS Transport PathwaysR01AG023084 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 2015 to 2019
$3.0M
The role of pericytes in the adult and the aging brainR01AG039452 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZLOKOVIC, BERISLAV V · 2011 to 2015
$1.6M
Brain pericyte contractility, cerebral blood flow and blood-brain barrier integrity are impaired by normal aging and Alzheimer's disease amyloid-beta and are dependent on p75NTRR00AG058780 · NIA · UNIVERSITY OF SOUTH ALABAMA · PI NELSON, AMY R · 2020 to 2022
$716k
Brain pericyte contractility, cerebral blood flow and blood-brain barrier integrity are impaired by normal aging and Alzheimer's disease amyloid-beta and are dependent on p75NTRK99AG058780 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NELSON, AMY R · 2018 to 2019
Recent studies revealed that cellular prion protein on neurons bind Alzheimer's amyloid-β oligomers, causing neurotoxic effects. A new article in Cell Reports by Gunther and colleagues (Cell Rep. 2019; 26:145-158) shows that an orally administered cellular prion protein antagonist can rescue synaptic and cognitive deficits in Alzheimer's mice overexpressing amyloid-β.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prion Protein Antagonists Rescue Alzheimer's Amyloid-β-Related Cognitive Deficits. · full record | OpenQuestion